Sustained Survival Benefit of Cemiplimab Plus Chemotherapy at 5 Years in Advanced NSCLC With PD-L1 ≥1%
Cimiplimab plus chemotherapy demonstrated a significant improvement in OS vs placebo plus chemotherapy in patients with PD-L1 ≥1% (median OS: 24.0 vs 12.1 months). Median PFS was also significantly prolonged in the cemiplimab combination arm (8.3 vs 5.5 months).
Få tilgang
Hvis du er lege, sykepleier eller annen helsepersonell, kan du få tilgang til hele artikkelen ved å opprette en profil på BestPractice Nordic.
- Få tilgang
- Hvis du allerede har en profil: Logg in
